1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hemorrhagic Fever - Pipeline Review, H2 2014

Hemorrhagic Fever - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 249 pages

Hemorrhagic Fever - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hemorrhagic Fever - Pipeline Review, H2 2014’, provides an overview of the Hemorrhagic Fever’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hemorrhagic Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hemorrhagic Fever - Pipeline Review, H2 2014
Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Hemorrhagic Fever Overview 10
Therapeutics Development 11
Pipeline Products for Hemorrhagic Fever - Overview 11
Pipeline Products for Hemorrhagic Fever - Comparative Analysis 12
Hemorrhagic Fever - Therapeutics under Development by Companies 13
Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 18
Hemorrhagic Fever - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Hemorrhagic Fever - Products under Development by Companies 24
Hemorrhagic Fever - Products under Investigation by Universities/Institutes 29
Hemorrhagic Fever - Companies Involved in Therapeutics Development 30
Adamas Pharmaceuticals, Inc. 30
AlphaVax, Inc. 31
Arbovax, Inc. 32
BioCryst Pharmaceuticals, Inc. 33
Chimerix, Inc. 34
Crucell N.V. 35
Epirus Biopharmaceuticals, Inc. 36
Evolva SA 37
FIT Biotech Oyj 38
GeoVax Labs, Inc. 39
GlaxoSmithKline plc 40
Hawaii Biotech, Inc. 41
Hemispherx Biopharma, Inc. 42
Humabs BioMed SA 43
iBio, Inc. 44
Immunovaccine, Inc. 45
Inovio Pharmaceuticals, Inc. 46
Integrated BioTherapeutics, Inc. 47
Janssen Pharmaceuticals, Inc. 48
Medicago Inc. 49
Microbiotix, Inc. 50
Myelo Therapeutics GmbH 51
NanoViricides, Inc. 52
Navigen Pharmaceuticals, Inc. 53
NewLink Genetics Corporation 54
Novavax, Inc. 55
Panacea Biotec Limited 56
Peregrine Pharmaceuticals, Inc. 57
Profectus BioSciences, Inc. 58
Sarepta Therapeutics, Inc. 59
SIGA Technologies, Inc. 60
Sihuan Pharmaceutical Holdings Group Ltd. 61
SKAU Vaccines ApS 62
Summit Corporation plc 63
Tekmira Pharmaceuticals Corp. 64
Themis Bioscience GmbH 65
Toyama Chemical Co., Ltd. 66
Vaxart, Inc. 67
Hemorrhagic Fever - Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Combination Products 69
Assessment by Target 70
Assessment by Mechanism of Action 72
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78
1-E703 - Drug Profile 78
ADS-324 - Drug Profile 79
ANSX-109 - Drug Profile 80
ANSX-142 - Drug Profile 81
Antibodies for Crimean Congo Hemorrhagic Fever - Drug Profile 82
ARD-5 - Drug Profile 83
AVI-7012 - Drug Profile 84
AVI-7288 - Drug Profile 85
bavituximab - Drug Profile 86
BCX-4430 - Drug Profile 91
BG-323 - Drug Profile 93
BPSC-1001 - Drug Profile 94
brincidofovir - Drug Profile 95
crimean-congo hemorrhagic fever vaccine - Drug Profile 97
DEF-201 - Drug Profile 98
dengue virus vaccine (tetravalent) - Drug Profile 100
DengueCide - Drug Profile 101
DiTU - Drug Profile 102
DNA Vaccines - Drug Profile 103
Drugs for Ebola and Marburg Infections - Drug Profile 104
ebola (virus like particles) vaccine - Drug Profile 105
ebola and marburg vaccine (trivalent) - Drug Profile 106
Ebola Vaccine - Drug Profile 108
ebola vaccine - Drug Profile 110
ebola vaccine - Drug Profile 111
Ebola Vaccine - Drug Profile 112
ebola vaccine - Drug Profile 113
ebola vaccine - Drug Profile 114
ebola vaccine - Drug Profile 115
ebola vaccine - Drug Profile 116
ebola vaccine - Drug Profile 117
ebola vaccine - Drug Profile 118
ebola vaccine - Drug Profile 119
ebola vaccine + marburg vaccine - Drug Profile 121
ebola vaccine [zaire] - Drug Profile 122
ebola virus vaccine - Drug Profile 123
EMER-IT - Drug Profile 124
ET-007 - Drug Profile 125
ETX-101 - Drug Profile 126
EV-075 - Drug Profile 127
favipiravir - Drug Profile 128
Filovirus Vaccine - Drug Profile 130
GOVXE-301 - Drug Profile 131
GOVXE-302 - Drug Profile 132
GreEMTri - Drug Profile 133
hemorrhagic fever (bivalent) vaccine - Drug Profile 134
imatinib mesylate - Drug Profile 135
INO-4200 - Drug Profile 136
interferon alfa-n3 - Drug Profile 137
JK-05 - Drug Profile 138
lassa fever vaccine - Drug Profile 139
lassa fever vaccine 1 - Drug Profile 140
lassa fever vaccine 2 - Drug Profile 141
LCTA-949 - Drug Profile 142
marburg vaccine - Drug Profile 143
marburg vaccine - Drug Profile 144
marburg virus vaccine - Drug Profile 145
MMCatLMC - Drug Profile 146
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 147
Monoclonal Antibodies for Rift Valley Fever - Drug Profile 148
Monoclonal Antibodies for Viral Infections - Drug Profile 149
Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Drug Profile 151
Monoclonal Antibody for Ebola Virus Infections - Drug Profile 152
Monoclonal Antibody for Marburg Virus - Drug Profile 153
MVA-BN-Filoviruses Vaccine - Drug Profile 154
Myelo-001 - Drug Profile 155
NoBola - Drug Profile 156
oxocarbazate - Drug Profile 157
panfilovirus (multivalent) vaccine - Drug Profile 158
rintatolimod - Drug Profile 159
Slit2N - Drug Profile 161
Small Molecule for Argentine Hemorrhagic Fever - Drug Profile 163
Small Molecule for Bunya Virus - Drug Profile 164
Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection - Drug Profile 165
Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections - Drug Profile 166
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 167
Small Molecules to Inhibit SAH Hydrolase for Ebola Virus Infection - Drug Profile 168
Small Molecules to Target Estrogen Receptor for Ebola Virus Infection - Drug Profile 169
SMT-15000 - Drug Profile 170
ST-161 - Drug Profile 171
ST-193 - Drug Profile 172
Synthetic Peptides for Ebola Virus - Drug Profile 173
thiocarbazate - Drug Profile 174
TKM-100701 - Drug Profile 175
TKM-100802 - Drug Profile 176
TKM-Marburg - Drug Profile 179
TSI-GSD-200 - Drug Profile 180
yellow fever and arenavirus vaccine - Drug Profile 181
yellow fever vaccine - Drug Profile 182
yellow fever vaccine - Drug Profile 183
yellow fever vaccine - Drug Profile 184
yellow fever vaccine - Drug Profile 185
yellow fever vaccine - Drug Profile 186
yellow fever vaccine - Drug Profile 187
yellow fever vaccine (YF17D) - Drug Profile 188
ZMAb - Drug Profile 189
ZMapp - Drug Profile 190
Hemorrhagic Fever - Recent Pipeline Updates 192
Hemorrhagic Fever - Dormant Projects 231
Hemorrhagic Fever - Discontinued Products 233
Hemorrhagic Fever - Product Development Milestones 234
Featured News and Press Releases 234
Appendix 242
Methodology 242
Coverage 242
Secondary Research 242
Primary Research 242
Expert Panel Validation 242
Contact Us 243
Disclaimer 243

List of Tables

Number of Products under Development for Hemorrhagic Fever, H2 2014 17
Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 25
Comparative Analysis by Late Stage Development, H2 2014 26
Comparative Analysis by Clinical Stage Development, H2 2014 27
Comparative Analysis by Early Stage Development, H2 2014 28
Comparative Analysis by Unknown Stage Development, H2 2014 29
Products under Development by Companies, H2 2014 30
Products under Development by Companies, H2 2014 (Contd..1) 31
Products under Development by Companies, H2 2014 (Contd..2) 32
Products under Development by Companies, H2 2014 (Contd..3) 33
Products under Development by Companies, H2 2014 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2014 35
Hemorrhagic Fever - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 36
Hemorrhagic Fever - Pipeline by AlphaVax, Inc., H2 2014 37
Hemorrhagic Fever - Pipeline by Arbovax, Inc., H2 2014 38
Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014 39
Hemorrhagic Fever - Pipeline by Chimerix, Inc., H2 2014 40
Hemorrhagic Fever - Pipeline by Crucell N.V., H2 2014 41
Hemorrhagic Fever - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 42
Hemorrhagic Fever - Pipeline by Evolva SA, H2 2014 43
Hemorrhagic Fever - Pipeline by FIT Biotech Oyj, H2 2014 44
Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2014 45
Hemorrhagic Fever - Pipeline by GlaxoSmithKline plc, H2 2014 46
Hemorrhagic Fever - Pipeline by Hawaii Biotech, Inc., H2 2014 47
Hemorrhagic Fever - Pipeline by Hemispherx Biopharma, Inc., H2 2014 48
Hemorrhagic Fever - Pipeline by Humabs BioMed SA, H2 2014 49
Hemorrhagic Fever - Pipeline by iBio, Inc., H2 2014 50
Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H2 2014 51
Hemorrhagic Fever - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 52
Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2014 53
Hemorrhagic Fever - Pipeline by Janssen Pharmaceuticals, Inc., H2 2014 54
Hemorrhagic Fever - Pipeline by Medicago Inc., H2 2014 55
Hemorrhagic Fever - Pipeline by Microbiotix, Inc., H2 2014 56
Hemorrhagic Fever - Pipeline by Myelo Therapeutics GmbH, H2 2014 57
Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2014 58
Hemorrhagic Fever - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 59
Hemorrhagic Fever - Pipeline by NewLink Genetics Corporation, H2 2014 60
Hemorrhagic Fever - Pipeline by Novavax, Inc., H2 2014 61
Hemorrhagic Fever - Pipeline by Panacea Biotec Limited, H2 2014 62
Hemorrhagic Fever - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 63
Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2014 64
Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2014 65
Hemorrhagic Fever - Pipeline by SIGA Technologies, Inc., H2 2014 66
Hemorrhagic Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2014 67
Hemorrhagic Fever - Pipeline by SKAU Vaccines ApS, H2 2014 68
Hemorrhagic Fever - Pipeline by Summit Corporation plc, H2 2014 69
Hemorrhagic Fever - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 70
Hemorrhagic Fever - Pipeline by Themis Bioscience GmbH, H2 2014 71
Hemorrhagic Fever - Pipeline by Toyama Chemical Co., Ltd., H2 2014 72
Hemorrhagic Fever - Pipeline by Vaxart, Inc., H2 2014 73
Assessment by Monotherapy Products, H2 2014 74
Assessment by Combination Products, H2 2014 75
Number of Products by Stage and Target, H2 2014 77
Number of Products by Stage and Mechanism of Action, H2 2014 79
Number of Products by Stage and Route of Administration, H2 2014 81
Number of Products by Stage and Molecule Type, H2 2014 83
Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H2 2014 198
Hemorrhagic Fever - Dormant Projects, H2 2014 237
Hemorrhagic Fever - Discontinued Products, H2 2014 239

List of Figures
Number of Products under Development for Hemorrhagic Fever, H2 2014 17
Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 19
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Clinical Stage Development, H2 2014 27
Comparative Analysis by Early Stage Products, H2 2014 28
Assessment by Monotherapy Products, H2 2014 74
Number of Products by Top 10 Targets, H2 2014 76
Number of Products by Stage and Top 10 Targets, H2 2014 76
Number of Products by Top 10 Mechanism of Actions, H2 2014 78
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 79
Number of Products by Top 10 Routes of Administration, H2 2014 80
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 81
Number of Products by Top 10 Molecule Types, H2 2014 82
Number of Products by Stage and Top 10 Molecule Types, H2 2014 83

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.